Filgotinib
Indication
Treating moderately to severely active ulcerative colitis - NICE TA792
NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis
MHRA Drug Safety Update, 26 April 2023
Red
Brand:
Nice TA:
792
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
1.1 Filgotinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:
-
when conventional or biological treatment cannot be tolerated, or
-
if the disease has not responded well enough or has stopped responding to these treatments, and
-
if the company provides filgotinib according to the commercial arrangement.